Biology leaves a record in blood. Switchpoint Bio reads it at scale.
Our solutions
Disease Biology & Biomarker Discovery
Reveal disease-driving cellular programs hidden in blood.
Patient Stratification & Trial Enrichment
Select patients by biology to strengthen treatment signal.
Treatment Response & Mechanism Readouts
Read how treatment shifts cellular biology over time.
“Too many diseases are still defined by symptoms, not by the biology that drives them. That has to change.
The future of therapeutic development needs biomarkers that are deep enough to explain biology and scalable enough to use in real trials.”
— Niilo Färkkilä, Co-Founder & Chief Commercial Officer
Disease Biology & Biomarker Discovery
SOLUTION
Identify disease-relevant biology and translate it into measurable biomarkers.
We sequence DNA methylation from blood or extracted DNA, resolving immune cell composition, epigenomic health history, and known and novel epigenetic risk markers for each sample.
Our computational models compare every profile against the Switchpoint Bio Reference Atlas, surfacing disease biology that standard clinical labels and biomarkers often miss, and tracing it back to the genes and pathways driving it.
WHAT WE DO
What biological subgroups exist within this disease, beyond current clinical labels?
Which immune cell states are associated with disease activity, severity, or progression?
Which genes and pathways are implicated, and how might that inform target or indication selection?
WHAT IT HELPS ANSWER
Disease subtype and cell-state maps built from your cohort, benchmarked against our reference atlas
Candidate methylation biomarkers, each traceable to the genes and pathways behind it
An evidence package — data, visuals, and biological interpretation — showing what the findings mean for target, indication, or translational strategy
WHAT YOU GET
Patient Stratification & Trial Enrichment
SOLUTION
Trials fail when biology is averaged away. We help identify the patient biology a therapy is designed to change.
Which patients are biologically different, despite sharing the same diagnosis?
Which biological subgroups are more likely to show a meaningful treatment signal?
How should that heterogeneity shape enrollment criteria in the next study?
WHAT IT HELPS ANSWER
Biologically defined patient segments, with a cellular profile describing what distinguishes each one
A candidate patient-selection signature you can apply prospectively to screen or stratify enrollment
An evidence package showing how cellular heterogeneity could affect treatment signal and study interpretation
WHAT YOU GET
We sequence baseline DNA methylation from archived or prospective study samples — before outcomes are known — resolving immune cell composition, environmental exposures, and other epigenomic layers for each patient.
We compare every profile against our reference atlas to uncover biologically defined patient groups, and test how those groups relate to disease activity, treatment history, and study endpoints.
WHAT WE DO
Treatment Response & Mechanism Readouts
SOLUTION
Read how treatment shifts cellular biology over time.
Is treatment shifting immune cell biology in the expected direction?
Which cellular shifts are associated with response or non-response?
Are the observed changes consistent with the therapy's expected mechanism of action?
Could the observed mechanism support expansion into new patient populations or indications?
WHAT IT HELPS ANSWER
Longitudinal cell-state profiles across baseline, on-treatment, and follow-up samples
Candidate pharmacodynamic markers linked to response, non-response, or loss of response
An evidence package linking observed biology to mechanism of action, supporting follow-on studies, indication expansion and label-expansion strategy.
WHAT YOU GET
We sequence DNA methylation across treatment timepoints — baseline, on-treatment, and follow-up — tracking shifts in immune cell composition and gene regulation as therapy unfolds.
We test whether those shifts associate with response, non-response, or loss of response, and whether they're consistent with the drug's expected mechanism of action.
WHAT WE DO
Where we focus today
Our platform is built for diseases where cellular state and immune biology shape progression, treatment response, and patient heterogeneity.
Today, that includes Inflammatory Bowel Disease (IBD), Systemic Lupus Erythematosus (SLE), Acute Myeloid Leukemia (AML), and Myelodysplastic Syndromes (MDS).
We welcome collaborations across other inflammatory, autoimmune, and immune-involved diseases where blood-based cellular readouts could advance both understanding and therapeutic development.
Partner with us
Switchpoint Bio works with biopharma and clinical research teams to generate decision-relevant cellular insight from blood-derived DNA.
Work with us on archived trial samples, biobank cohorts, or prospective studies to uncover disease biology, patient heterogeneity, and mechanisms of response.
For Biopharma Teams
Work with us to add scalable cellular profiling to deeply characterized cohorts and reveal disease biology, progression, and treatment effects.